Related Experiment Video

Updated: Jun 8, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Activation of platelets and cellular coagulation in cerebral small-vessel disease

Tom Oberheiden1, Christian Blahak, Xuan Duc Nguyen

  • 11st Department of Medicine, Germany.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|October 2, 2010
PubMed

Insights

Platelet and monocyte activation, indicated by elevated CD40L, CD62P, and aggregates, is present in cerebral small-vessel disease (cSVD). This activation may contribute to cSVD development, though not correlating with disease severity.

Area of Science:

  • Cardiovascular Research
  • Neurology
  • Hematology

Background:

  • Platelets and monocytes are crucial in large-vessel atherosclerosis.
  • Platelet and coagulation activation markers are elevated in cardiovascular diseases and acute cerebral ischemia.

Purpose of the Study:

  • To investigate the role of platelets and cellular coagulation activation in cerebral small-vessel disease (cSVD).

Main Methods:

  • Assessed platelet and monocyte activation markers (CD40L, CD62P, tissue factor) and platelet-monocyte aggregates via flow cytometry in 24 cSVD patients.
  • Measured plasma levels of soluble CD40L, IL-6, and IL-7 using ELISA.
  • Compared findings to 10 healthy controls.

Main Results:

  • cSVD patients exhibited significantly higher platelet CD40L and CD62P expression, increased platelet-monocyte aggregates, and enhanced monocyte tissue factor exposure compared to controls.
  • Significantly lower plasma IL-7 levels were observed in cSVD patients.
  • Platelet and monocyte activation did not correlate with cSVD severity (Fazekas scores).

Conclusions:

  • Patients with cSVD demonstrate an upregulation of the platelet CD40L and CD62P system.
  • Cellular coagulation activation is evident in cSVD patients.
  • This activation may play a role in the initiation and progression of cSVD.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...